Bristol-Myers Squibb has signed a definitive agreement to sell its ConvaTec business unit to Nordic Capital Fund VII and Avista Capital Partners for approximately $4.1 billion.
McKesson has reached administrative and civil settlements with the US Drug Enforcement Administration and six US Attorneys' Offices regarding the company's distribution of so-called lifestyle drugs.
Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals's lead nicotinic alpha-7 agonist drug candidate, MEM 3454, for neurological and psychiatric disorders.
St Jude Medical has announced a partnership with the Microsoft Health Solutions Group to research the integration of data from implantable devices with patient-controlled, personal health records.
MedImmune's researchers has presented positive results from Phase III study involving motavizumab, an investigational monoclonal antibody that is being evaluated for its potential to prevent serious disease caused by respiratory syncytial virus in high-risk pediatric patients.
Mpathy Medical has raised new equity finance from Archangel Informal Investment and Scottish Enterprise's co-investment fund. The funds are being used to launch its products in the US.
Basilea Pharmaceutica has announced that the Therapeutic Products Directorate of Health Canada has accepted for review its new drug submission of oral alitretinoin for the treatment of severe refractory chronic hand eczema.
Medical device company Lumenis has announced plans to align their ophthalmic strategic business unit, Lumenis Vision, for aggressive growth while at the same time ensuring standards of quality and reliability.
Cardiva Medical has closed a $15.5 million private equity financing lead by PTV Sciences. Cardiva intends to use the proceeds of the financing for general corporate purposes, including the expansion of its US sales force.
Advantage Medical Devices has received FDA's market clearance for the company's new safety engineered short-term peripheral intra-venous catheter, VantageCath.
Bovie Medical Corporation has announced a CE Mark for its Modular Ergonomic Instruments, allowing the MEG Laparoscopic line to be marketed throughout the European Union.
Epix Pharmaceuticals has begun Phase IIb program in Alzheimer's disease through the initiation of a clinical trial of PRX-03140, its novel 5-HT4 agonist, in combination with donepezil.
Minrad International has entered into agreements to issue and sell an aggregate of $40 million of senior secured convertible notes with a group of institutional accredited investors in a private placement.
Biotechnology company Mologen has received approval from the relevant health authorities to carry out a Phase I study using company's MGN1703 cancer drug, which is based on the dSLIM DNA immunomodulator.
GE Healthcare has signed a non-exclusive agreement with Merck & Co, to share technology on imaging of the lungs that may help to advance respiratory treatment development.
